Marathon Pharmaceuticals reportedly withdrew from the drug industry’s lobbying group yesterday following controversy over its pricey drug, Emflaza.
Pharmaceutical Research and Manufacturers of America (PhRMA) began reconsidering its membership criteria as reports revealed a number of drugmakers hiking the prices of their products. In February, Marathon revealed it planned to charge $89,000 a year for Emflaza, even though generic versions go for around $1,000.
Marathon joins drug manufacturer Mallinckrodt Pharmaceuticals (NYSE:MNK), which resigned from the industry trade group in the beginning of April.
Get the full story at our sister site, Drug Delivery Business News.
The post Mallinckrodt, Marathon leave industry trade group over drug pricing controversy appeared first on MassDevice.
